Top Markets
Coin of the day
Tectonic Therapeutic, Inc. Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc.

TECX
Rank in Stocks #11671
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm... Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Share Price
$35.63
Last synced: 2026-08-28
Market Cap
$672.28M
Change (1 day)
-2.92%
Change (1 year)
39.50%
Country
US
Trade Tectonic Therapeutic, Inc. (TECX)

Category

P/B ratio for Tectonic Therapeutic, Inc. (TECX)
P/B ratio as of 2026 TTM: 0
According to Tectonic Therapeutic, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Tectonic Therapeutic, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH